Kontour Medical released its 2024 annual performance, with a net profit attributable to the parent company of 88.4 million yuan, a year-on-year increase of 17.07%
Kontour Medical released its 2024 annual performance, achieving revenue of 322 million yuan during the reporting period, a year-on-year increase of 17.06%; the net profit attributable to shareholders was 88.4 million yuan, a year-on-year increase of 17.07%. The company plans to distribute a cash dividend of 1.8 yuan for every 10 shares to all shareholders. The core products in neurosurgery performed outstandingly, with total revenue from PEEK materials and titanium materials reaching 278.0188 million yuan, accounting for 89.19% of the main business income. The company continues to optimize its products through technological innovation, consolidating its leading position in the field of neurosurgical repair and fixation
According to the Zhitong Finance APP, Kontour Medical (688314.SH) disclosed its 2024 annual report, showing that the company achieved revenue of 322 million yuan during the reporting period, a year-on-year increase of 17.06%; net profit attributable to shareholders was 88.4 million yuan, a year-on-year increase of 17.07%; net profit excluding non-recurring gains and losses was 74.86 million yuan, a year-on-year increase of 9.52%; basic earnings per share were 1.09 yuan. The company plans to distribute a cash dividend of 1.8 yuan (including tax) for every 10 shares to all shareholders.
Core products in the neurosurgery field performed outstandingly, with total revenue from PEEK materials and titanium materials reaching 278.0188 million yuan, a year-on-year increase of 14.09%, accounting for 89.19% of main business revenue. Among them, PEEK material products achieved revenue of 205.8373 million yuan, a year-on-year increase of 23.33%, with the proportion of main business revenue increasing by 2.48 percentage points to 66.03%; titanium material products achieved revenue of 72.1814 million yuan, accounting for 23.16% of main business revenue, a decrease of 6.08 percentage points compared to the same period last year.
The company seizes the opportunity of regional centralized procurement policies, accelerates the clinical replacement of traditional titanium material products with PEEK material products, and successfully launched the "4D Bioactive Plate" and a full PEEK material cranial repair solution. During the reporting period, the company continuously optimized its products through technological innovation, enhancing patient postoperative experience and consolidating its leading position in the field of neurosurgery repair and fixation
